

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
20 March 2008 (20.03.2008)

PCT

(10) International Publication Number
WO 2008/033764 A2

(51) International Patent Classification:

A61K 31/517 (2006.01) C07D 401/02 (2006.01)
 A61K 31/5377 (2006.01) C07D 403/02 (2006.01)
 A61K 31/551 (2006.01) C07D 413/14 (2006.01)
 A61P 25/00 (2006.01)

(21) International Application Number:

PCT/US2007/078022

(22) International Filing Date:

10 September 2007 (10.09.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/843,718 11 September 2006 (11.09.2006) US

(71) Applicant (for all designated States except US): N.V.
 ORGANON [NL/NL]; Kloosterstraat 6, NL-5349 AB Oss
 (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LETOURNEAU,


Jeffrey [US/US]; 6 Bristol Way, East Windsor, NJ 08520
 (US). JOKIEL, Patrick [US/US]; 2 Scarlet Oak Drive,
 Princeton, NJ 08540 (US). NAPIER, Elizabeth [GB/GB];
 c/o Organon Laboratories Ltd., New Edinburgh Road,
 Newhouse, Lanarkshire ML1 5SH (GB). HO, Koc-Kan
 [US/US]; 77 Warwick Road, West Windsor, NJ 08850
 (US). OHLMEYER, Michael [US/US]; 6 Beechtree
 Lane, Plainsboro, NJ 08536 (US). MCARTHUR, Dun-
 can, Robert [GB/GB]; c/o Organon Laboratories Ltd.,
 New Edinburgh Road, Newhouse, Lanarkshire ML1
 5SH (GB). FIONA, Jeremiah [GB/GB]; c/o Organon
 Laboratories Ltd., New Edinburgh Road, Newhouse,
 Lanarkshire ML1 5SH (GB). RATCLIFFE, Paul, David
 [GB/GB]; c/o Organon Laboratories Ltd., New Edinburgh
 Road, Newhouse, Lanarkshire ML1 5SH (GB). JURGEN,
 Schulz [DE/GB]; c/o Organon Laboratories Ltd., New
 Edinburgh Road, Newhouse, Lanarkshire ML1 5SH (GB).

(74) Agent: HESS, Susan; Organon International Inc., 56 Liv-
 ington Avenue, Roseland, NJ 07068 (US).


(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH,

[Continued on next page]

(54) Title: QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES



I



II

(57) Abstract: The present invention relates to a quinazolinone or isoquinolinone derivative of formula I, wherein R¹ is C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₃alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, said C₁₋₆alkyl, C₃₋₆cycloalkyl and C₃₋₆cycloalkylC₁₋₃alkyl being optionally substituted with hydroxy, C₁₋₆alkyloxy, cyano or one or more halogens; R² is C₆₋₁₀aryl optionally substituted with one to three substituents selected from halogen, hydroxy, cyano, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₁₋₆alkyloxy and C₃₋₆cycloalkyloxy, said C₁₋₆alkyl, C₃₋₆cycloalkyl, C₁₋₆alkyloxy and C₃₋₆cycloalkyloxy being optionally substituted with one or more halogens; or R² is a 5-10 membered heteroaryl ring system comprising a heteroatom selected from N, O and S and optionally substituted with a substituent selected from methyl, C₁₋₆alkyloxy and halogen; or R² is C₄₋₇cycloalkyl; R³ is an optional substituent selected from C₁₋₆alkyl, C₁₋₆alkyloxy and halogen, said C₁₋₆alkyl and C₁₋₆alkyloxy being optionally substituted with one or more halogens; R⁴ is a group located at the 6- or 7- position of the quinazolinone or isoquinolinone ring having the formula II, wherein R⁵ together with one of R⁶ forms a 4-8 membered saturated or unsaturated heterocyclic ring optionally comprising a further heteroatomic moiety selected from O, S and NR, said

heterocyclic ring being optionally substituted with one or two substituents selected from methyl, halogen, hydroxy and oxo or R⁵ together with one of R⁷ and R⁸ forms a 6-8 membered heterocyclic ring optionally substituted with one or two substituents selected from methyl, halogen, hydroxy and oxo; Each R⁶ is independently H, halogen or C₁₋₄alkyl optionally substituted with halogen or SO₂CH₃ or one of R⁶ together with R⁵ forms a 4-8 membered saturated or unsaturated heterocyclic ring optionally comprising a further heteroatomic moiety selected from O, S and NR⁹, said heterocyclic ring being optionally substituted with one or two substituents selected from methyl, halogen, hydroxy and oxo; R⁷ and R⁸ are independently H, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₃alkyl, cyanoC₁₋₃alkyl, C₆₋₁₀aryl, C₆₋₁₀arylC₁₋₃alkyl, C₁₋₃alkyloxyC₁₋₃alkyl or C₁₋₆acyl said C₁₋₆alkyl, C₃₋₆cycloalkyl and C₃₋₆cycloalkylC₁₋₃alkyl being optionally substituted with hydroxy, 1 or more halogens or diC₁₋₂alkylamino; or R⁷ and R⁸ together with the nitrogen to which they are bonded form a 4-8 membered saturated or unsaturated heterocyclic ring optionally comprising a further heteroatomic moiety selected from O, S and NR¹⁰, said heterocyclic ring being optionally substituted with one or two substituents selected from C₁₋₆alkyl, halogen, hydroxy,

WO 2008/033764 A2



CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH,

Published:

— *without international search report and to be republished upon receipt of that report*